IS8. Advances in Women’s Mental Health: A Decade of Progress Supported by Eli Lilly and Company

A. Effects of Gonadal Steroids on Brain and Behavior David R. Rubinow, M.D.

B. SSRIs in the Treatment of PMDD: A Critical Review Adele C. Viguera, M.D.

C. Course and Treatment of Mood Disorders During Pregnancy and the Postpartum Period Lee S. Cohen, M.D.

D. Psychopharmacology During Pregnancy and Lactation: Determining Infant Exposure Zachary N. Stowe, M.D.

E. Mood Disorders in Perimenopause: The Estrogen Connection Hadine Joffe, M.D.

IS9. From Neurobiology to Novel Treatments: Applications in Alzheimer’s Disease Supported by Novartis Pharmaceuticals Corporation

A. Multidisciplinary Management of the Patient with Alzheimer’s Disease: A Case History Murray A. Raskind, M.D.

B. Etiology of Alzheimer’s Disease: Evolving Theories Paul R. Solomon, Ph.D.

C. Emerging Therapeutic Options in Alzheimer’s Disease Gary W. Small, M.D.

D. The Role of the Psychiatrist in Optimizing Outcomes in Alzheimer’s Disease: Facilitating Cooperation Across Specialties Elaine Peskind, M.D.

IS10. Images of Anxiety Supported by SmithKline Beecham Pharmaceuticals

A. Advances in Neuroimaging Jack M. Gorman, M.D.

B. Panic Disorder and GAD Justine M. Kent, M.D.

C. PTSD: A Mind’s-Eye View Murray B. Stein, M.D.

D. Social Anxiety Disorder Franklin R. Schneier, M.D.

E. Images of Social Anxiety Disorder: A Five-Year Video Case Study Daniel D. Christensen, M.D.

IS11. Treatment Practice and Promise for Schizophrenia in the New Millennium Supported by Janssen Pharmaceutica and Research Foundation

A. Toward the Primary Prevention of Schizophrenia Ming T. Tsuang, M.D.

B. Long-Term Outcome: Staying the Course Nina R. Schooler, Ph.D.

C. Optimal Use of Atypical Antipsychotics Samuel J. Keith, M.D.

D. Childhood-Onset Schizophrenia Christopher J. McDougle, M.D.

E. Therapeutic Implications of the Glutamate Model of Schizophrenia Donald C. Goff, M.D.

IS12. Advances in the Treatment of Insomnia Supported by Wyeth-Ayerst Laboratories

A. Prevalence, Phenomenology, and Consequences of Insomnia Daniel J. Buysse, M.D.

B. Circadian Rhythm Disorders and Insomnia: Treatment with Melatonin, Phototherapy, and Chronotherapy Gary Richardson, M.D.

C. Behavioral Intervention for Chronic Insomnia Jack D. Edinger, Ph.D.

D. Pharmacotherapy for Insomnia W. Vaughn McCall, M.D.

IS13. Novel Treatments for Depression Supported by Merck U.S. Health

A. Current Status of Managing Depression: Is There a Need for New Treatment Strategies? Alan F. Schatzberg, M.D.

B. Substance P Antagonist: Mechanisms of Action and Clinical Implications Dennis S. Charney, M.D.

C. Corticotropin-Releasing Factor Antagonists: Promising Therapy for Depression Charles B. Nemeroff, M.D.

D. Transcranial Magnetic Stimulation: Magnets in Depression K. Ranga R. Krishnan, M.D.

E. Evidence-Based Psychotherapy: Improving Patient Outcomes Myrna M. Weissman, Ph.D.

IS14. Individualizing Management of Depressive Disorders Supported by
Organon Inc.

A. Sexual Dysfunction Associated with Treatment of Major Depression Anita L.H. Clayton, M.D.

B. Weight Gain Associated with Long-Term Antidepressant Therapy Norman Sussman, M.D.

C. Management of Antidepressant Nonresponders Jerrold F. Rosenbaum, M.D.

D. Linking Antidepressant Therapy to Medical Outcomes P. Murali Doraiswamy, M.D.

IS15. Family Violence: Victimization and Perpetration Supported by U.S. Pharmaceuticals, Pfizer Inc.

A. Domestic Violence: Context and Treatment Carole L. Warshaw, M.D.

B. Beyond PTSD: Adaptation to Domestic Trauma Bessel A. Van Der Kolk, M.D.

C. Creating Sanctuary: Toward the Evolution of Sane Societies Sandra L. Bloom, M.D.

D. PTSD and Addictive Disorders: Concurrent Treatment Paula G. Panzer, M.D.

E. Violent Children Elissa P. Benedek, M.D.

IS16. Managing Patients with Acute Psychosis: An Interactive Program Supported by Janssen Pharmaceutica and Research Foundation

A. Neurobiology of Aggressive Behavior Jean-Pierre Lindenmayer, M.D.

B. Involuntary Treatment Renee L. Binder, M.D.

C. Initial Pharmacologic Management of Episodic Agitation Michael H. Allen, M.D.

D. The Impact of the Second-Generation Antipsychotics on Aggression Among Psychotic Patients K.N. Roy Chengappa, M.D.

E. Maximizing Long-Term Compliance and Functional Outcome Robert R. Conley, M.D.

IS17. Controversies at the Interface of Sleep and Psychiatry Supported by Wyeth-Ayerst Laboratories

A. Sleep Disturbance in Mood and Anxiety Disorders Thomas A. Mellman, M.D.

B. Mood Regulation: Function of REM Sleep and Dreaming Rosalind Cartwright, Ph.D.

C. Medications for Sleep Disorders Wallace B. Mendelson, M.D.

D. Defining Optimal Sleep Thomas Roth, Ph.D.

IS18. Pharmacotherapy of Depression: New Strategies Supported by Pharmacia & Upjohn Company Inc.

A. Mechanism of Action and Clinical Response Alan Frazer, Ph.D.

B. Anxiety and Depression Jack M. Gorman, M.D.

C. Sexual Dysfunction and Depression Robert M.A. Hirschfeld, M.D.

D. Sleep and Depression Michael E. Thase, M.D.

E. Compliance and Tolerability Steven P. Roose, M.D.

IS19. Bipolar Children and Adolescents: Controversies in Diagnosis and Treatment Supported by Abbott Laboratories

A. Bipolar Spectrum Disorder: Genetic Hypotheses David A. Mrazek, M.D.

B. Controversies in Making the Diagnosis Peter S. Jensen, M.D.

C. Controversies in the Treatment of Difficult Bipolar Adolescents Karen D. Wagner, M.D.

D. Evaluation and Management of Violent Behavior in Bipolar Adolescents Hans Steiner, M.D.

E. Neuroimaging and Neuropsychological Testing Robert L. Hendren, D.O.

IS20. Complexities of Treatment of Bipolar Disorder Supported by Glaxo Wellcome Inc.

A. Recent Genetic Findings in Bipolar Disorder John I. NurnbergerJr., M.D.

B. Distinctive Mixed States of Bipolar I, II, and Beyond Hagop S. Akiskal, M.D.

C. Ethics Issues in Bipolar Disorder William B. Lawson, M.D.

D. Women with Bipolar Illness: Special Issues Katherine L. Wisner, M.D.

IS21. Bipolar Disorder and Schizophrenia: Acute and Long-Term Issues American Society of Clinical Psychopharmacology; Supported by Bristol-Myers Squibb Company

A. Recognition and Treatment of Acute Bipolar Illness Lori L. Altshuler, M.D.

B. Bipolar Disorder: Maintenance Treatment Alan J. Gelenberg, M.D.

C. Early Detection and Intervention in Schizophrenia Barbara Cornblatt, Ph.D.

D. Long-Term Treatment of Schizophrenia John M. Kane, M.D.

E. Minimizing Risks to Maximize Benefits of Long-Term Treatment James W. Jefferson, M.D.

L1. Frontiers of Decision-Making Competence Thomas Grisso, M.D., and Paul Appelbaum, M.D., AAPL/APA’s Manfred S. Guttmacher Award Lecture

IS22. Neurobiology of Disease: From the Lab to the Clinic Supported by SmithKline Beecham Pharmaceuticals

A. Recent Advances in the Neurobiology of Mood and Anxiety Disorders Dennis S. Charney, M.D.

B. Novel Actions of Antidepressants Charles B. Nemeroff, M.D.

C. Use of Functional Brain Imaging in Understanding Major Psychiatric Disorders: Profiles and Promises Clinton D. Kilts, Ph.D.

D. Antidepressant Management of Interferon-Induced Sequelae Dominique L. Musselman, M.D.

E. Anxiety Disorders and Irritable Bowel Syndrome R. Bruce Lydiard, M.D.

IS23. Pharmacotherapy in Dementia: Expanding the Boundaries Supported by Eisai Inc., Pfizer Inc.

A. Pharmacology of Dementia: Expanding the Boundaries P. Murali Doraiswamy, M.D.

B. Pharmacotherapy of Cognition in Dementia Trey Sunderland, M.D.

C. Pharmacotherapy of Depression in Dementia George S. Alexopoulos, M.D.

D. Pharmacotherapy of Agitation in Dementia Prakash S. Masand, M.D.

E. Pharmacotherapy of Apathy in Dementia Michael S. Mega, M.D.

IS24. New Antipsychotics: From Practice to Theory Supported by AstraZeneca Pharmaceuticals

A. Subjective Response to Atypical Antipsychotic Medication Donna A. Wirshing, M.D.

B. The Efficacy Spectrum for Atypicals in Clinical Practice Ira D. Glick, M.D.

C.The Management of Treatment-Refractory Schizophrenia: Experiences from the Front Line Peter F. Buckley, M.D.

D. Adverse Experiences with Newer Antipsychotics Stephen R. Marder, M.D.

E. Newer Antipsychotics and Psychiatric Rehabilitation Stephen R. Marder, M.D.

F. Combining New Antipsychotics with Other Treatments Heinz Katschnig, M.D.

IS25. Recurrent Depression: Challenges and Solutions Supported by Forest Laboratories Inc.

A. Maximizing Acute-Phase Treatment Michael E. Thase, M.D.

B. The Role of Psychotherapy in Chronic Depression Jan Scott, M.D.

C. Managing Chronic Depression Lauren B. Marangell, M.D.

D. Long-Term Prophylactic Studies of Depression: What Do They Mean in Practice? Alan Wade, M.B.

E. Challenges in Depression: A Case-Based Problem-Solving Panel A. John Rush, M.D.

IS26. Violence and Its Prevention: The Role of Psychiatry Supported by Eli Lilly and Company

A. Personality Disorders and Impulsive Aggression Emil F. Coccaro, M.D.

B. Depression and Anger Attacks Maurizio Fava, M.D.

C. Impact of Newer Antipsychotic Agents on Violence in Psychosis K.N. Roy Chengappa, M.D.

D. Violent Behavior and Substance Abuse: Preventive and Treatment Approaches Kathleen T. Brady, M.D.

E. A Cycle of Trauma: Violence and PTSD Kathryn M. Connor, M.D.

IS27. Novel Precipitants of Anxiety Supported by Solvay Pharmaceuticals Inc.

A. Precipitants of Anxiety in Children and Adolescents Daniel S. Pine, M.D.

B. Precipitants of Anxiety in Response to Noncombat Trauma Phebe M. Tucker, M.D.

C. Anxiety Disorders Across Cultures Dan J. Stein, M.D.

D. Repetitive Behaviors and the Regulation of Anxiety Eric Hollander, M.D.

E. Precipitants of Anxiety in Social Situations Murray B. Stein, M.D.

IS28. From Patients to People: Redefining Wellness in Psychosis Supported by U.S. Pharmaceuticals, Pfizer Inc.

A. Early Intervention in Schizophrenia John M. Kane, M.D.

B. Assessment and Treatment of Acute Psychotic Agitation Alan J. Mendelowitz, M.D.

C. Broadening the Spectrum of Antipsychotic Efficacy Rajiv Tandon, M.D.

D. Raising Standards and Switching Medications Peter J. Weiden, M.D.

E. Atypical Antipsychotics: Enhancing Healthy Outcomes Daniel E. Casey, M.D.

1. The Piano Forum for the Psychoanalytic Study of Film

2. Three Seasons